Soffio Medical
Medical apparatus for respiratory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
N/A | Series A | ||
| Total Funding | 000k | ||
Related Content
Soffio Medical, Inc. was a privately held medical device company established in 2014 by co-founders Howard Levin and Mark Gelfand. Headquartered in Boston, Massachusetts, the firm focused on developing therapeutic devices for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). The company secured funding from institutional investors, including SV Health Investors and Norwich Ventures, raising a total of $2 million through seed and Series A financing rounds.
The core of Soffio Medical's strategy was the development of implantable devices aimed at improving the quality of life for patients with respiratory conditions. Their technology centered on an airway bypass concept designed to vent air trapped in areas of the lung affected by high-resistance airways. By reducing residual lung volume, the device intended to alleviate the symptoms associated with COPD. The company's intellectual property portfolio included several patents for methods and devices related to treating hyper-inflated lungs. Despite its efforts in developing these medical apparatuses, Soffio Medical is now listed as out of business as of December 2017.
Dr. Howard Levin, a co-founder, is a cardiologist by training and a serial inventor in the biomedical engineering field. His work has led to the successful launch of several medical technology companies, including Ardian (acquired by Medtronic), eValve (acquired by Abbott), and Respicardia. This background in cardiology and creating novel medical devices was directly relevant to Soffio's mission to address complex respiratory and cardiovascular-related health issues. Mark Gelfand, the other co-founder, also has a track record of founding another company in the medical space.
Keywords: Soffio Medical, medical devices, respiratory disease, chronic obstructive pulmonary disease, COPD, implantable devices, airway bypass, Howard Levin, Mark Gelfand, SV Health Investors, Norwich Ventures, therapeutic devices, hyper-inflated lung, medical apparatus, out of business, formerly VC-backed